Informed Momentum Co LLC Has $2.66 Million Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Key Points

• Informed Momentum Co LLC increased its stake in Delcath Systems by 218.7%, owning approximately 0.62% of the company worth $2.656 million as of its latest SEC filing.
• Delcath Systems reported an EPS of $0.07 for the recent quarter, exceeding analysts' estimates of $0.02, and had revenues of $24.16 million against expectations of $22.84 million.
• Analyst ratings for Delcath Systems are mixed, with one holding a "hold" rating and four giving a "buy" rating, resulting in an average target price of $24.50.

Informed Momentum Co LLC raised its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 218.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 208,604 shares of the company's stock after buying an additional 143,157 shares during the period. Informed Momentum Co LLC owned about 0.62% of Delcath Systems worth $2,656,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Quarry LP bought a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $34,000. Inlight Wealth Management LLC bought a new stake in shares of Delcath Systems during the first quarter valued at approximately $85,000. Graham Capital Management L.P. bought a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $123,000. NBC Securities Inc. grew its stake in shares of Delcath Systems by 99,900.0% during the first quarter. NBC Securities Inc. now owns 10,000 shares of the company's stock valued at $127,000 after purchasing an additional 9,990 shares during the last quarter. Finally, PharVision Advisers LLC bought a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $129,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Stephens reissued an "overweight" rating and set a $25.00 price target on shares of Delcath Systems in a research note on Monday, June 23rd. Wall Street Zen cut shares of Delcath Systems from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Finally, HC Wainwright raised their price objective on shares of Delcath Systems from $29.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $24.50.

Delcath Systems Stock Down 1.1%

DCTH stock traded down $0.11 during midday trading on Friday, reaching $10.36. The company's stock had a trading volume of 434,276 shares, compared to its average volume of 852,871. The business's 50-day simple moving average is $12.39 and its 200-day simple moving average is $13.42. The stock has a market cap of $362.40 million, a PE ratio of 207.20 and a beta of 0.82. Delcath Systems, Inc. has a 52 week low of $7.45 and a 52 week high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.05. The company had revenue of $24.16 million for the quarter, compared to analyst estimates of $22.84 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. As a group, equities analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.